The settlement resolves allegations that BMC billed Medicare for more units of an expensive cancer drug, Rituxan, than it actually infused in its patients. After learning of the investigation, BMC informed the federal government that it had undertaken an audit of the Rituxan issue.
The settlement also resolves allegations that BMC overbilled Medicare and Medicaid for services at its pre-surgical treatment center and submitted claims to Medicare for outpatient podiatry services where clinical documentation did not support the necessity of the services, according to the DOJ.
The allegations were originally brought by Kathleen Haffernan, BMC’s former chief compliance officer, under the whistle-blower provision of the False Claims Act.
More articles on healthcare industry lawsuits:
Physician imposter treats patients in Michigan, helps steal $6.2M from Medicare
Legal battle over Broward Health chairman’s reinstatement heads to appeals court
FTC heads to trial to stop Hershey-Pinnacle merger: 3 things to know
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
